Sutro Biopharma, Inc. (STRO)
STRO moved a median of -0.56% 30 minutes after news, and +0.32% by the close. How STRO actually reacts to news — the realized, point-in-time move the market made, measured across 271 labeled events over the last three years with zero look-ahead.
STRO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 271 |
| 30-min | -0.56% | 41% | 271 |
| 60-min | -0.83% | 36% | 271 |
| to close | +0.32% | 53% | 270 |
| Middle 50% of STRO reactions | -2.70% to +1.01% |
|---|---|
| Median reaction (30-min) | -0.56% |
| Measured reactions | 271 |
Half of all Sutro Biopharma, Inc. news events land between -2.70% and +1.01% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How STRO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | -1.69% | 41% | +1.41% |
| Analyst downgrades | 17 | -9.98% | 18% | -18.99% |
| Coverage initiations | 20 | -0.18% | 40% | -0.49% |
| Rating reiterations | 71 | -0.27% | 45% | +0.54% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how STRO ranks against every other measured name →
That’s how STRO usually reacts — get an email when it moves on news →Email me when STRO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to STRO's baseline. Nothing else.
Recent STRO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference | Press release | GlobeNewswire | +0.07% | -5.68% | |
| Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development | Press release | GlobeNewswire | +0.69% | +0.31% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.18% | -9.71% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -3.18% | -9.71% | |
| Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study | Press release | GlobeNewswire | -3.18% | -9.71% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.96% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.92% | -11.13% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -9.92% | -11.13% | |
| Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | -9.92% | -11.13% | |
| Form ARS SUTRO BIOPHARMA, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.89% | -3.06% | |
| Form DEF 14A SUTRO BIOPHARMA, INC. For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | -1.89% | -3.06% | |
| Form DEFA14A SUTRO BIOPHARMA, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -1.89% | -3.06% | |
| Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 | Press release | GlobeNewswire | +1.40% | +9.60% | |
| Form EFFECT SUTRO BIOPHARMA, INC. | SEC filing · Form EFFECT | SEC EDGAR | +1.49% | -1.37% | |
| Form 10-K SUTRO BIOPHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.29% | +1.55% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -6.29% | +1.55% | |
| Form S-3 SUTRO BIOPHARMA, INC. | SEC filing · Form S-3 | SEC EDGAR | -6.29% | +1.55% | |
| Form S-8 SUTRO BIOPHARMA, INC. | SEC filing · Form S-8 | SEC EDGAR | -6.29% | +1.55% | |
| Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -6.29% | +1.55% | |
| Sutro Biopharma to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.13% | +4.87% | |
| Sutro Biopharma Announces Participation at the 16th World ADC London Summit | Press release | GlobeNewswire | +2.90% | -0.33% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | +2.94% | |
| Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering | Press release | GlobeNewswire | -5.85% | -8.05% | |
| Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.21% | +0.43% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -3.88% | -0.89% | |
| Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | -3.88% | -0.89% | |
| Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.41% | -8.24% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -4.50% | +14.11% | |
| Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors | Press release | GlobeNewswire | -7.13% | +12.26% | |
| Sutro Biopharma Announces 1-for-10 Reverse Stock Split | Press release | GlobeNewswire | +0.00% | -5.71% | |
| Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day | Press release | GlobeNewswire | -2.11% | -1.84% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.04% | -9.30% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -4.04% | -9.30% | |
| Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -4.04% | -9.30% | |
| Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025 | Press release | GlobeNewswire | +1.09% | -2.96% | |
| Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference | Press release | GlobeNewswire | -2.68% | -1.79% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -1.32% | |
| Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones | Press release | GlobeNewswire | -0.11% | -1.32% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.13% | -0.22% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -0.22% | |
| Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | +1.13% | -0.22% | |
| Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates | Press release | GlobeNewswire | +3.26% | +5.66% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.13% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +0.52% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | +1.48% | |
| Sutro Biopharma Appoints Greg Chow as Chief Financial Officer | Press release | GlobeNewswire | +0.03% | +2.97% | |
| Form S-8 SUTRO BIOPHARMA, INC. | SEC filing · Form S-8 | SEC EDGAR | +0.03% | +2.97% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.35% | -12.85% | |
| Form 8-K SUTRO BIOPHARMA, INC. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -12.85% | |
| Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -0.35% | -12.85% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the STRO section they belong to.
Where else STRO is measured.
STRO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InspireMD Inc. (NSPR) | 271 | 0.00% | 39% |
| Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) | 271 | -0.69% | 33% |
| PRESBIA PLC ORDINARY SHARES (LENS) | 270 | 0.00% | 42% |
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sutro Biopharma, Inc.'s median reaction calculated?
Every labeled STRO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 271 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of STRO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does STRO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.